Balanced news tone
News Sentiment
PBLS sentiment intelligence
Parabilis Medicines, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
52 relevant articles
News tone and price action are not far from neutral.
84/100 classification confidence.
directly relevant articles
high-authority source matches
+2.7% over one week, - over four weeks, trend inactive, and near fair-value range.
PBLS Stock: Price, Forecast, Financials & AI Analysis
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
84/100 classification
One-week reaction
2.7%
Price confirming higher
Trend fit
Trend inactive
Weekly context
Fair value
6.1%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
15
Neutral
34
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Quiver Quantitative
Direct company coverage
PBLS | Parabilis Medicines, Inc. Common Stock Data, Price & News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 02:52
- Source
- Quiver Quantitative
Bloomberg.com
Direct company coverage
Drugmaker Parabilis Raises $745 Million in US IPO, Placement
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Bloomberg.com
Market source
Direct company coverage
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Market source
Reuters
Direct company coverage
Parabilis Medicines targets $2.3 billion valuation in upsized US IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Reuters
CNN
Direct company coverage
symbol__ Stock Quote Price and Forecast
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 05 Jun 2026 20:49
- Source
- CNN
Reuters
Direct company coverage
Parabilis Medicines aims to raise up to $475 million in US IPO
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- Reuters
Seeking Alpha
Direct company coverage
Regeneron backed Parabilis seeks up to $476M in U.S. IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- Seeking Alpha
eciks.org
Direct company coverage
UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+
- Tone
- Positive 84/100
- Event
- Earnings
- Published
- 26 May 2026 07:00
- Source
- eciks.org
Seeking Alpha
Direct company coverage
Regeneron backed Parabilis Medicines seeks U.S. IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- Seeking Alpha
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Investopedia
Direct company coverage
UnitedHealth Group Stock Soars on Strong Earnings, Boosted Outlook
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Investopedia
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Investopedia
Direct company coverage
How Much Is UnitedHealth Group Stock Expected to Move After Earnings?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Apr 2026 07:00
- Source
- Investopedia
Market source
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Market source
Kavout | AI
Direct company coverage
Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Feb 2026 09:53
- Source
- Kavout | AI
TIKR.com
Direct company coverage
Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 25 Feb 2026 08:00
- Source
- TIKR.com
Barron's
Direct company coverage
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Barron's
simplywall.st
Industry context
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 09 Dec 2025 08:00
- Source
- simplywall.st